Microbix Biosystems Inc. is a life science enterprise dedicated to advancing human health globally, including markets across North America and Europe. Established in 1988 and headquartered in Mississauga, Canada, the company specializes in developing and marketing unique biological and technological products. A significant part of its business involves producing essential biological reagents for the diagnostic industry. This encompasses antigens vital for immunoassays, alongside its distinctive Quality Assessment and Proficiency (QAP) products. These QAPs are instrumental for clinical laboratories, providing support for proficiency testing, the development and validation of diagnostic assays, and optimizing routine lab operations. Furthermore, Microbix applies its deep biological knowledge and infrastructure to create additional proprietary offerings. Among these are DxTM, a viral transport medium crucial for stabilizing patient specimens prior to laboratory analysis, and Kinlytic Urokinase, a biopharmaceutical thrombolytic drug employed to treat blood clots. The company channels its QAP sales to accreditation organizations, diagnostic companies, and clinical laboratories via an extensive network of regional distributors.
Subscribe to see Microbix Biosystems Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Microbix Biosystems Inc. is a biotech company headquartered in Mississauga, Canada. Its most recent funding round raised $43,303 in July 2021. Xcout tracks 19 named people at Microbix Biosystems Inc., including Steven L. Hoerter (Executive Chairperson, CEO & President).
13 more named people on record for Microbix Biosystems Inc., with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $43,303 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Microbix Biosystems Inc.'s closest competitors — see the full list of competitors and alternatives →
Precision BioLogic Inc. is headquartered in Dartmouth, Nova Scotia, Canada. The privately held company specializes in manufacturing and supplying frozen diagnostic products.
AXIM Biotechnologies, Inc. specializes in the creation and distribution of advanced diagnostic solutions for healthcare, focusing on critical areas such as SARS-CoV-2 (COVID-19), ocular health, and cancer treatment. The company is currently developing rapid diagnostic assays that quantify functional neutralizing antibodies, which are essential for preventing the SARS-CoV-2 virus from attaching to human cells. Additionally, it offers serological diagnostic tests designed to detect neutralizing antibodies, thereby assessing the body's adaptive immune response to the virus, and is developing tests to identify inflammation biomarkers for the effective management of COVID-19 patients. For eye health, AXIM is pioneering quick, quantitative tear tests to measure Matrix metalloproteinase-9, an inflammatory marker associated with dry eye disease. In its oncology pipeline, the firm is advancing SBI-183, an anti-metastatic compound engineered to inhibit tumor cell growth and block the spread of cancer, as well as SPX-1009, another anti-metastatic therapy aimed at determining the levels of quiescin sulfhydryl oxidase I. Established in 2010, the company was formerly known as Axim International Inc. before officially changing its name to AXIM Biotechnologies, Inc. in July 2014, and it is headquartered in San Diego, California.
Sansure Biotech Inc., founded in Changsha, China, in 2008, is dedicated to the global development and commercialization of advanced diagnostic and research products. The company offers a diverse range of solutions, including upstream nucleic acid extraction kits, real-time PCR systems for both clinical and investigative purposes, and fluorescence detection platforms. Their extensive product portfolio encompasses diagnostic assays for critical conditions like the novel coronavirus, viral hepatitis, and AIDS. Furthermore, they provide blood screening and general extraction kits, tests for cancer-related biomarkers, and solutions for respiratory, sexually transmitted, digestive tract, prenatal, postnatal, and genetic diseases. Sansure Biotech also supplies essential laboratory instrumentation and various consumables, primarily serving hospitals and scientific laboratories worldwide.
Kohjin Bio Co., Ltd., established in 1981 in Sakado, Japan, and known as Kohjin Co.,Ltd. until its rebranding in 1989, is a diversified life science enterprise. The company's core business involves the production and sale of various biological materials, including animal blood, sera, cell culture media, agar media for microbial assays, in-vitro diagnostic products, and cosmetics. Its extensive catalog for cell and tissue culture features specialized mediums crucial for virus and recombinant protein synthesis, hybridoma development, human lymphocyte cultivation, and insect cell lines. Additionally, Kohjin Bio supplies complementary items such as gas-permeable cell culture bags, cryopreservation agents, medium supplements, normal human cells along with their growth media, ES cell media, and comprehensive kits for in-vitro fertilization and early embryo culture. The firm further provides essential laboratory tools like cell separation solutions, physiological salt solutions, and a range of research reagents. Within microbiology, Kohjin Bio offers a wide array of culture media tailored for various applications. For clinical diagnostics, this includes mediums for identifying gram-positive cocci and gram-negative bacteria, susceptibility testing, general differentiation, anaerobic growth, and fungal detection, alongside tube mediums for confirmatory tests and expansion. For food safety, their products cover sterilization assessments, and the detection of E. coli, coliform bacteria, Staphylococcus spp., Bacillus cereus, and Vibrio parahaemolyticus. The company also produces mediums for total viable cell count determination and specific media for Campylobacter and fungi. The company's blood and serum division offers normal human blood, serum, and plasma, as well as pathological human serum. Its animal blood portfolio encompasses preserved, defibrinated, and hemolyzed animal blood, in addition to animal serum and plasma, with custom-designed formulations like Eagle medium also available. Beyond its manufacturing activities, Kohjin Bio engages in the breeding and distribution of laboratory animals, the sale of medical equipment, and provides contract services for animal immunization and antibody preparation. The company also manages the import and export of its diverse products and raw materials internationally.
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
MicroVizual Inc. develops a tape-based infrastructure platform that automates and digitizes histology workflows for research and clinical environments. The company's proprietary technology replaces traditional glass slides with continuous roll media to improve sample handling, throughput, and AI-readiness in pathology.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.